Jim Simons Gamida Cell Ltd. Transaction History

Renaissance Technologies LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.25 - $1.02 $239,395 - $976,732	957,581 New	957,581 $395,000
Q1 2022 May 13, 2022	SELL	$2.22 - $4.47 $654,456 - $1.32 Million	-294,800 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$2.2 - $4.46 $520,044 - $1.05 Million	-236,384 Reduced 44.5%	294,800 $749,000
Q3 2021 Nov 12, 2021	BUY	$3.85 - $6.44 $1.24 Million - $2.07 Million	321,484 Added 153.31%	531,184 $2.08 Million
Q2 2021 Aug 13, 2021	BUY	$5.85 - $8.33 $805,468 - $1.15 Million	137,687 Added 191.2%	209,700 $1.34 Million
Q1 2021 May 13, 2021	BUY	$7.8 - $12.43 $561,701 - $895,121	72,013 New	72,013 $583,000
Q4 2020 Feb 10, 2021	SELL	$4.07 - $11.0 $77,663 - $209,902	-19,082 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$3.93 - $4.59 $1.01 Million - $1.18 Million	-257,218 Reduced 93.09%	19,082 $79,000
Q2 2020 Aug 13, 2020	BUY	$2.79 - $6.5 $770,877 - $1.8 Million	276,300 New	276,300 $1.26 Million

2.2K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.